226 related articles for article (PubMed ID: 15950471)
21. Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase.
Selness SR; Devraj RV; Monahan JB; Boehm TL; Walker JK; Devadas B; Durley RC; Kurumbail R; Shieh H; Xing L; Hepperle M; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R
Bioorg Med Chem Lett; 2009 Oct; 19(20):5851-6. PubMed ID: 19751974
[TBL] [Abstract][Full Text] [Related]
22. Identification of novel inhibitors of extracellular signal-regulated kinase 2 based on the structure-based virtual screening.
Park H; Bahn YJ; Jeong DG; Woo EJ; Kwon JS; Ryu SE
Bioorg Med Chem Lett; 2008 Oct; 18(20):5372-6. PubMed ID: 18835158
[TBL] [Abstract][Full Text] [Related]
23. Discovery of indazoles as inhibitors of Tpl2 kinase.
Hu Y; Cole D; Denny RA; Anderson DR; Ipek M; Ni Y; Wang X; Thaisrivongs S; Chamberlain T; Hall JP; Liu J; Luong M; Lin LL; Telliez JB; Gopalsamy A
Bioorg Med Chem Lett; 2011 Aug; 21(16):4758-61. PubMed ID: 21742493
[TBL] [Abstract][Full Text] [Related]
24. 3D-QSAR and docking studies of aminopyridine carboxamide inhibitors of c-Jun N-terminal kinase-1.
Yi P; Qiu M
Eur J Med Chem; 2008 Mar; 43(3):604-13. PubMed ID: 17602798
[TBL] [Abstract][Full Text] [Related]
25. Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors.
Dublanchet AC; Ducrot P; Andrianjara C; O'Gara M; Morales R; Compère D; Denis A; Blais S; Cluzeau P; Courté K; Hamon J; Moreau F; Prunet ML; Tertre A
Bioorg Med Chem Lett; 2005 Aug; 15(16):3787-90. PubMed ID: 16002291
[TBL] [Abstract][Full Text] [Related]
26. Design and synthesis of Rho kinase inhibitors (II).
Iwakubo M; Takami A; Okada Y; Kawata T; Tagami Y; Ohashi H; Sato M; Sugiyama T; Fukushima K; Iijima H
Bioorg Med Chem; 2007 Jan; 15(1):350-64. PubMed ID: 17046269
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
Sawyer JS; Anderson BD; Beight DW; Campbell RM; Jones ML; Herron DK; Lampe JW; McCowan JR; McMillen WT; Mort N; Parsons S; Smith EC; Vieth M; Weir LC; Yan L; Zhang F; Yingling JM
J Med Chem; 2003 Sep; 46(19):3953-6. PubMed ID: 12954047
[TBL] [Abstract][Full Text] [Related]
28. Kinase array design, back to front: biaryl amides.
Baldwin I; Bamborough P; Haslam CG; Hunjan SS; Longstaff T; Mooney CJ; Patel S; Quinn J; Somers DO
Bioorg Med Chem Lett; 2008 Oct; 18(19):5285-9. PubMed ID: 18789685
[TBL] [Abstract][Full Text] [Related]
29. Discovery and design of benzimidazolone based inhibitors of p38 MAP kinase.
Hammach A; Barbosa A; Gaenzler FC; Fadra T; Goldberg D; Hao MH; Kroe RR; Liu P; Qian KC; Ralph M; Sarko C; Soleymanzadeh F; Moss N
Bioorg Med Chem Lett; 2006 Dec; 16(24):6316-20. PubMed ID: 17010605
[TBL] [Abstract][Full Text] [Related]
30. Identification of small-molecule inhibitors of the JIP-JNK interaction.
Chen T; Kablaoui N; Little J; Timofeevski S; Tschantz WR; Chen P; Feng J; Charlton M; Stanton R; Bauer P
Biochem J; 2009 May; 420(2):283-94. PubMed ID: 19243309
[TBL] [Abstract][Full Text] [Related]
31. Structural requirements of isoquinolones as novel selective c-Jun N-terminal kinase 1 inhibitors: 2D and 3D QSAR analyses.
Du J; Xi L; Lei B; Liu H; Yao X
Chem Biol Drug Des; 2011 Apr; 77(4):248-54. PubMed ID: 21276204
[TBL] [Abstract][Full Text] [Related]
32. Development of indole/indazole-aminopyrimidines as inhibitors of c-Jun N-terminal kinase (JNK): optimization for JNK potency and physicochemical properties.
Gong L; Han X; Silva T; Tan YC; Goyal B; Tivitmahaisoon P; Trejo A; Palmer W; Hogg H; Jahagir A; Alam M; Wagner P; Stein K; Filonova L; Loe B; Makra F; Rotstein D; Rapatova L; Dunn J; Zuo F; Dal Porto J; Wong B; Jin S; Chang A; Tran P; Hsieh G; Niu L; Shao A; Reuter D; Hermann J; Kuglstatter A; Goldstein D
Bioorg Med Chem Lett; 2013 Jun; 23(12):3565-9. PubMed ID: 23664880
[TBL] [Abstract][Full Text] [Related]
33. Three-dimensional quantitative structure-activity relationship (3 D-QSAR) and docking studies on (benzothiazole-2-yl) acetonitrile derivatives as c-Jun N-terminal kinase-3 (JNK3) inhibitors.
Shaikh AR; Ismael M; Del Carpio CA; Tsuboi H; Koyama M; Endou A; Kubo M; Broclawik E; Miyamoto A
Bioorg Med Chem Lett; 2006 Nov; 16(22):5917-25. PubMed ID: 16989998
[TBL] [Abstract][Full Text] [Related]
34. IRAK-4 inhibitors. Part II: a structure-based assessment of imidazo[1,2-a]pyridine binding.
Buckley GM; Ceska TA; Fraser JL; Gowers L; Groom CR; Higueruelo AP; Jenkins K; Mack SR; Morgan T; Parry DM; Pitt WR; Rausch O; Richard MD; Sabin V
Bioorg Med Chem Lett; 2008 Jun; 18(11):3291-5. PubMed ID: 18482836
[TBL] [Abstract][Full Text] [Related]
35. Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase.
Tamayo N; Liao L; Goldberg M; Powers D; Tudor YY; Yu V; Wong LM; Henkle B; Middleton S; Syed R; Harvey T; Jang G; Hungate R; Dominguez C
Bioorg Med Chem Lett; 2005 May; 15(9):2409-13. PubMed ID: 15837335
[TBL] [Abstract][Full Text] [Related]
36. Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants.
Breitenlechner CB; Friebe WG; Brunet E; Werner G; Graul K; Thomas U; Künkele KP; Schäfer W; Gassel M; Bossemeyer D; Huber R; Engh RA; Masjost B
J Med Chem; 2005 Jan; 48(1):163-70. PubMed ID: 15634010
[TBL] [Abstract][Full Text] [Related]
37. Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole lead.
Palmer WS; Alam M; Arzeno HB; Chang KC; Dunn JP; Goldstein DM; Gong L; Goyal B; Hermann JC; Hogg JH; Hsieh G; Jahangir A; Janson C; Jin S; Ursula Kammlott R; Kuglstatter A; Lukacs C; Michoud C; Niu L; Reuter DC; Shao A; Silva T; Trejo-Martin TA; Stein K; Tan YC; Tivitmahaisoon P; Tran P; Wagner P; Weller P; Wu SY
Bioorg Med Chem Lett; 2013 Mar; 23(5):1486-92. PubMed ID: 23352510
[TBL] [Abstract][Full Text] [Related]
38. Scaffold oriented synthesis. Part 4: design, synthesis and biological evaluation of novel 5-substituted indazoles as potent and selective kinase inhibitors employing heterocycle forming and multicomponent reactions.
Akritopoulou-Zanze I; Wakefield BD; Gasiecki A; Kalvin D; Johnson EF; Kovar P; Djuric SW
Bioorg Med Chem Lett; 2011 Mar; 21(5):1480-3. PubMed ID: 21288717
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors.
Laufer SA; Domeyer DM; Scior TR; Albrecht W; Hauser DR
J Med Chem; 2005 Feb; 48(3):710-22. PubMed ID: 15689155
[TBL] [Abstract][Full Text] [Related]
40. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.
McInnes C; Wang S; Anderson S; O'Boyle J; Jackson W; Kontopidis G; Meades C; Mezna M; Thomas M; Wood G; Lane DP; Fischer PM
Chem Biol; 2004 Apr; 11(4):525-34. PubMed ID: 15123247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
